IDO2 and non-small cell lung carcinoma: Activation of PKM2 also induces the release of paclitaxel and indoleamine 2,3-dioxygenase (IDO) inhibitors, augmenting the efficacy of immunochemotherapy in non-small cell lung cancer (NSCLC) [106].